Presentation is loading. Please wait.

Presentation is loading. Please wait.

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.

Published byCandice Abigayle Simmons Modified over 6 years ago

Similar presentations

Presentation on theme: "Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical."— Presentation transcript:

1 Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical Lipidology  Volume 2, Issue 2, Pages S29-S33 (April 2008) DOI: /j.jacl Copyright © 2008 National Lipid Association Terms and Conditions

2 Figure 1 Bile acids upregulate farnesoid X receptor (FXR), which in turn downregulates oxysterol liver X receptor (LXR) (mediated by small heterodimer partner [SHP]). Therefore, colesevelam hydrochloride, a bile acid sequestrant, would likely decrease FXR expression and release by inhibition of LXR. LXR upregulation increases expression of adenosine triphosphate (ATP)–binding cassette transporter 1 (ABCA1) and ATP-binding cassette, subfamily G(ABCG1), which enhances reverse cholesterol transport and ATP-binding cassette, sub-family G (WHITE), member 5 (ABCG5) and ATP-binding cassette transporter protein (ABCG8), which would decrease intestinal cholesterol absorption. Journal of Clinical Lipidology 2008 2, S29-S33DOI: ( /j.jacl ) Copyright © 2008 National Lipid Association Terms and Conditions

3 Figure 2 Colesevelam hydrochloride: effects on lipids in diabetes. ApoB, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. Journal of Clinical Lipidology 2008 2, S29-S33DOI: ( /j.jacl ) Copyright © 2008 National Lipid Association Terms and Conditions

4 Figure 3 Glucose-Lowering Effect of Welchol Study (GLOWS): change in A1C. Journal of Clinical Lipidology 2008 2, S29-S33DOI: ( /j.jacl ) Copyright © 2008 National Lipid Association Terms and Conditions

5 Figure 4 Colesevelam hydrochloride (HCL) added to an insulin-based regimen. Change in A1C from baseline at 16 weeks. Journal of Clinical Lipidology 2008 2, S29-S33DOI: ( /j.jacl ) Copyright © 2008 National Lipid Association Terms and Conditions

6 Figure 5 Colesevelam hydrochloride (HCl) added to a metformin-based regimen. A1C change in A1C at week 26. Journal of Clinical Lipidology 2008 2, S29-S33DOI: ( /j.jacl ) Copyright © 2008 National Lipid Association Terms and Conditions

7 Figure 6 Effects of colesevelam on hemoglobin A1C levels in add-on therapy trials; ≥0.50% reductions. GLOWS, Glucose-Lowering Effect of Welchol Study; HCl, hydrochloride. Journal of Clinical Lipidology 2008 2, S29-S33DOI: ( /j.jacl ) Copyright © 2008 National Lipid Association Terms and Conditions

Download ppt "Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical."

Similar presentations

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
Figure 6 Cholesterol metabolism in obesity-related glomerulopathy

Figure 6 Cholesterol metabolism in obesity-related glomerulopathy
Volume 146, Issue 4, Pages (April 2014)

Volume 146, Issue 4, Pages (April 2014)
Dyslipidemia in chronic kidney disease: Causes and consequences

Dyslipidemia in chronic kidney disease: Causes and consequences
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
An assessment by the Statin Liver Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
Volume 146, Issue 4, Pages (April 2014)

Volume 146, Issue 4, Pages (April 2014)
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,
A review of PCSK9 inhibition and its effects beyond LDL receptors

A review of PCSK9 inhibition and its effects beyond LDL receptors
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,

Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,
Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:
Figure 4 Acute-phase HDL

Figure 4 Acute-phase HDL
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia  Joep C. Defesche, PhD,

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia  Joep C. Defesche, PhD,

Similar presentations

Ads by Google